Protagenic Therapeutics, Inc.\new: 10-Q filed 2023-05-15

Name: Protagenic Therapeutics, Inc.\new: 10-Q filed 2023-05-15
Creator: Protagenic Therapeutics, Inc.\new

What Protagenic Therapeutics, Inc.\new reported in its quarterly report filed 2023-05-15 (fiscal Q1 2023): 26 published measures, 53 facts as tagged in accession 0001493152-23-017171.

This filing

Form: 10-Q (quarterly report)
Filed: 2023-05-15
Fiscal period: fiscal Q1 2023
Accession: 0001493152-23-017171 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Protagenic Therapeutics, Inc.\new filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2023-03-31	7,666,288	USD
At 2022-12-31	8,037,420	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2023-03-31	1,251,975	USD
At 2022-12-31	1,119,862	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2023-03-31	6,414,313	USD
At 2022-12-31	6,917,558	USD
At 2022-03-31	8,719,583	USD
At 2021-12-31	9,941,955	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-718,096	USD	90
2022-01-01 to 2022-03-31	-1,362,109	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-371,834	USD	90
2022-01-01 to 2022-03-31	-430,565	USD	90

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	0	USD	90
2022-01-01 to 2022-03-31	0	USD	90

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	294,669	USD	90
2022-01-01 to 2022-03-31	370,763	USD	90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2023-03-31	-26,495,471	USD
At 2022-12-31	-25,777,375	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	4,317,875	shares	90
2022-01-01 to 2022-03-31	4,308,413	shares	90

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-0.17	USD/shares	90
2022-01-01 to 2022-03-31	-0.32	USD/shares	90

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2023-03-31	1,685	USD
At 2022-12-31	1,775	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	166,707	USD	90
2022-01-01 to 2022-03-31	235,779	USD	90

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-739,294	USD	90
2022-01-01 to 2022-03-31	-1,341,276	USD	90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2023-03-31	7,664,603	USD
At 2022-12-31	8,035,645	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	31,263	USD	90
2022-01-01 to 2022-03-31	33,844	USD	90

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2023-03-31	1,251,975	USD
At 2022-12-31	1,119,862	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	739,294	USD	90
2022-01-01 to 2022-03-31	1,341,276	USD	90

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	348,031	USD	90
2022-01-01 to 2022-03-31	669,838	USD	90

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2023-03-31	4,330,959	shares
At 2022-12-31	4,321,315	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2023-03-31	33,538,113	USD
At 2022-12-31	33,371,406	USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2023-03-31	-628,763	USD
At 2022-12-31	-676,907	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-718,096	USD	90
2022-01-01 to 2022-03-31	-1,362,109	USD	90

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-669,952	USD	90
2022-01-01 to 2022-03-31	-1,513,119	USD	90

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	391,263	USD	90
2022-01-01 to 2022-03-31	671,438	USD	90

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	90	USD	90

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	21,198	USD	90
2022-01-01 to 2022-03-31	-20,833	USD	90

Inspect the source

Entity: Protagenic Therapeutics, Inc.\new / CIK 0001022899
Captured: 2026-09-20T05:13:45.961Z
SEC response SHA-256: 65b45c5addd26cd3e105dbeb1582537b1352dc73c447a8d926c77d81587fc033

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001022899.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))